The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 136,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Genomics in pharma: embryonic stem cell culturing. Buy the report here.

Smarter leaders trust GlobalData

Data Insights Innovation in Pharmaceuticals: Embryonic stem cell culturing

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

Johnson & Johnson

Bristol-Myers Squibb Co

Astellas Pharma Inc

Vertex Pharmaceuticals Inc

View all

According to GlobalData’s Technology Foresights, which uses over 730,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.

Embryonic stem cell culturing is a key innovation area in Genomics

Embryonic stem cells are cells derived from the human embryo and, owing to its pluripotent characteristics, they have a wide range of therapeutic applications. Embryonic culture helps in cultivating an embryo under aseptic conditions on a nutrient medium. Embryonic culture is of two types, namely mature and immature embryo culture.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 335+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of embryonic stem cell culturing.

Key players in embryonic stem cell culturing – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to embryonic stem cell culturing

Johnson & Johnson is the leading patent filer in embryonic stem cell culturing. The company is involved in developing several regenerative medicines and human embryonic stem cells. It also entered several agreements with other companies for the development of embryonic stem cells. It has established the Committee on Advanced Therapies to ensure standards are maintained during cell culturing.

In terms of application diversity, UK Research is the top company, followed by Emulate and Nexel.

By means of geographic reach, Bristol-Myers Squibb also holds the top position, while Imstem Biotechnology and Takeda Pharmaceutical are in the second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Genomics.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.